IBCSG 25-02: A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer (TEXT).

Trial Profile

IBCSG 25-02: A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer (TEXT).

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Exemestane (Primary) ; Triptorelin (Primary) ; Tamoxifen
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Acronyms TEXT
  • Most Recent Events

    • 05 Jun 2018 Results assessing absolute improvements in freedom from distant recurrence in patients from SOFT and TEXT trials (n=4891), presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 04 Jun 2018 Results assessing absolute improvements in freedom from distant recurrence in patients from SOFT and TEXT trials presented in a Dana-Farber Cancer Institute media release.
    • 04 Jun 2018 Results of the updated analysis of SOFT and TEXT trials, published in the New England Journal of Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top